Anixa Biosciences (ANIX) Current Assets (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Current Assets came in at $14.7 million in Q2 2026, down 12.37% YoY from $16.8 million in Q2 2025, and down 7.52% on a QoQ basis from $15.9 million in Q4 2025.
Anixa Biosciences (ANIX) Current Assets (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Current Assets data on file, last reported at $14.7 million in Q2 2026.
- Quarterly Current Assets fell 12.37% year-over-year to $14.7 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $14.7 million (down 12.37% YoY) and the FY2025 annual result came in at $15.9 million, down 25.63% from the prior year.
- Current Assets fell to $14.7 million in Q2 2026, from $15.9 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $35.0 million in Q1 2022 to a low of $14.7 million in Q2 2026.
- A 5-year average of $24.4 million and a median of $25.2 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets surged 140.27% — and 2025, when it plunged 30.76%.
- Tracing ANIX's Current Assets over 5 years: stood at $30.2 million in 2022, then dropped by 16.04% to $25.4 million in 2023, then fell by 15.75% to $21.4 million in 2024, then slipped by 25.63% to $15.9 million in 2025, then retreated by 7.52% to $14.7 million in 2026.
- The last three Current Assets figures came in at $14.7 million (Q2 2026), $15.9 million (Q4 2025), and $17.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 1.76 Bn |
| 10 | Anixa Biosciences | 122.61 Mn | 122.61 Mn | - | 14.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 14.69 Mn |
| Oct 31, 2025 | 15.89 Mn |
| Jul 31, 2025 | 17.45 Mn |
| Apr 30, 2025 | 16.77 Mn |
| Jan 31, 2025 | 18.69 Mn |
| Oct 31, 2024 | 21.36 Mn |
| Jul 31, 2024 | 22.67 Mn |
| Apr 30, 2024 | 24.21 Mn |
| Jan 31, 2024 | 25.22 Mn |
| Oct 31, 2023 | 25.36 Mn |
| Jul 31, 2023 | 26.40 Mn |
| Apr 30, 2023 | 27.41 Mn |
| Jan 31, 2023 | 28.11 Mn |
| Oct 31, 2022 | 30.20 Mn |
| Jul 31, 2022 | 32.34 Mn |
| Apr 30, 2022 | 32.56 Mn |
| Jan 31, 2022 | 34.99 Mn |
| Oct 31, 2021 | 36.00 Mn |
| Jul 31, 2021 | 37.05 Mn |
| Apr 30, 2021 | 38.47 Mn |